Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
60 participants
INTERVENTIONAL
2006-08-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure
NCT01863511
Feasibility Assessment of the Aquadex FlexFlowTM Ultrafiltration System in Treating Non Hospitalized Heart Failure Patients in Dedicated Heart Failure Centers
NCT01654926
Renal Denervation to Treat Heart Failure With Preserved Ejection Fraction
NCT05030987
Renal Artery Denervation in Chronic Heart Failure
NCT01584700
Loop Diuretic Therapy in Acutely Decompensated Heart Failure
NCT02638142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ultrafiltration
Ultrafiltration treatment
ultrafiltration
Usual treatment
Usual HF treatment
ultrafiltration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ultrafiltration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ejection fraction \< 40%
* Estimated fluid overload \> 4 kg
Exclusion Criteria
* Acute pulmonary edema and/or cardiogenic shock
20 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centro Cardiologico Monzino
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Piergiuseppe Agostoni
MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Piergiuseppe Agostoni, MD.PhD
Role: PRINCIPAL_INVESTIGATOR
Centro Cardiologico Monzino
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Cardiologico Monzino
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Marenzi G, Muratori M, Cosentino ER, Rinaldi ER, Donghi V, Milazzo V, Ferramosca E, Borghi C, Santoro A, Agostoni P. Continuous ultrafiltration for congestive heart failure: the CUORE trial. J Card Fail. 2014 Jan;20(1):9-17. doi: 10.1016/j.cardfail.2013.11.004. Epub 2013 Nov 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCM S67/306
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.